MdxHealth (TM) : MDxHealth Announces Publication of the Clinical Utility of Combining Genetics and Epigenetics to Improve

 MdxHealth (TM) : MDxHealth Announces Publication of the Clinical Utility of
 Combining Genetics and Epigenetics to Improve Management of Prostate cancer

IRVINE, CA, and LIEGE, BELGIUM - 8:00  AM, April 3, 2013 - MDxHealth SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic tests to  support cancer treatment, today  announced 
the publication of the clinical utility of epigenetic diagnosis to improve the
management of prostate cancer.  The results were published  in the Journal  of 
Oncopathology 2013;1:29-32.

In this publication, researchers  from the University  of Gent, Johns  Hopkins 
and  MDxHealth  reported  on  the  imminent  shift  towards   sequencing-based 
diagnostic technologies utilized in obtaining a clinical diagnosis of prostate
cancer anticipated in the near future. Profiling and integrating genetic  and 
epigenetic aberrations that are implicated  in prostate cancer will allow  for 
rapid identification  and  development  of  molecular  diagnostic  assays.  By 
directing efforts  toward  the  selection  of  known  epigenetic  and  genomic 
targets, an  immediate  improvement  tool  in  the  diagnosis,  treatment  and 
long-term   management    of    these    patients    can    be    expected 
(http://www.oncopathology.doctors.md/Vol1IssueI.html).

"Technological advances in the field of  sequencing are redefining the era  of 
personalized disease profiling," noted Prof Dr. Wim van Criekinge, Head of the
Laboratory of Bioinformatics and Computational  Genomics at the University  of 
Gent. "Previously, profiling was limited  to one modality of gene  regulation, 
e.g. the  identification  of  somatic  mutations,  without  considering  other 
changes that are occurring concomitantly. Now genomic and epigenomic  profiles 
of all, or a very large set of,  genes known to be implicated in the onset  of 
cancer,  disease  progression  or  the  prediction  of  therapeutic  efficacy, 
regardless   of   their   frequency   of   occurrence,   can   be   determined 
simultaneously."

"Combining comprehensive,  integrated, molecular  profiles with  clinical  and 
therapeutic outcomes  serves  as a  powerful,  evidence-based method  for  the 
identification of  biomarkers,"  stated  Dr.  Jan  Groen,  CEO  of  MDxHealth. 
"Applying  next  generation  and   targeted  deep  sequencing   technologies, 
MDxHealth has  developed tests  that improve  the diagnosis  and treatment  of 
prostate cancer as well as other cancer types."

About ConfirmMDx^TM for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year;
though approximately 25% of these men may still harbor occult prostate cancer.
This  well-documented  risk  of  undetected  cancer,  often  with   clinically 
significant Gleason scores, leads to a high rate of repeat biopsies with  over 
40% of men receiving at least one repeat biopsy, and many receiving a 3^rd and
4^th biopsy. Today's gold standard diagnostic approach is the prostate  biopsy 
procedure, collecting 10-12 needle core biopsy samples, however this  sampling 
represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is
an epigenetic  assay  to  help  urologists distinguish  patients  who  have  a 
true-negative biopsy from those at risk for occult cancer. The test is able to
detect an epigenetic field effect or "halo" associated with the  cancerization 
process at the  DNA level  in cells adjacent  to cancer  foci. This  molecular 
"halo" around  a  cancer  lesion  can  be  present  despite  having  a  normal 
appearance under the microscope. The  test helps urologists rule out  prostate 
cancer-free men from undergoing unnecessary repeat biopsies and helps rule  in 
high risk patients who may require repeat biopsies and potential treatment.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The company's first  commercial product, ConfirmMDx for  Prostate 
Cancer, has been shown to help  distinguish patients who have a  true-negative 
biopsy from those who may have undetected cancer. MDxHealth helps to address a
large and growing unmet medical need for better cancer diagnosis and treatment
information. The company has  a proprietary platform  and a strong  epigenetic 
product pipeline focused on  the development of  products for prostate,  brain 
and lung cancers. The company is  based in Irvine, California with a  European 
headquarters in Liege, Belgium. For more information visit MDxHealth's website
at www.mdxhealth.com.

For more information:

Dr Jan Groen           Mike Sinclair           Seth Lewis
President and CEO
MDxHealth              Halsin Partners         The Trout Group
US: +1 949 812 6979 UK: +44 20 7318 2955   US: +1 646 378 2952
BE: +32 4 364 20 70    Cell: +44 7968 022075
info@mdxhealth.com   msinclair@halsin.com slewis@troutgroup.com



This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.



NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

Click here for the PDF version

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1689481